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Kaposi’s sarcoma occurs at high incidence among Zambian adults and children, but there is a paucity of data on
human herpesvirus 8 (HHV-8) incidence and routes of infection, especially in children. Between 1998 and 2004,
the authors conducted a prospective study of viral transmission in a cohort of 684 children in Lusaka, Zambia, to
estimate the annual incidence of HHV-8 from birth through 48 months of age. Maternal and pediatric human
immunodeficiency virus type 1 (HIV-1) infection status was also determined. The results, based on 1,532 child-
years of follow-up, showed that HHV-8 seroconversion occurs early in life. The incidence rate of HHV-8 serocon-
version was 13.8 infections per 100 child-years by 48 months of age. HIV-1-infected children were at substantially
higher risk for HHV-8 seroconversion (adjusted hazard ratio¼ 4.60, 95% confidence interval: 2.93, 7.22). Maternal
HIV-1 and HHV-8 infection status were not independently associated with risk of HHV-8 seroconversion in the
child. HHV-8 antibody titers in children followed at all consecutive time points revealed seroreversion of HHV-8
antibodies, with undetectable titers in some children at one or more time points after seroconversion. These results
demonstrate that cross-sectional serologic screening probably underestimates true HHV-8 seroprevalence in
young Zambian children because of fluctuations in detectable antibody titers.
herpesvirus 8, human; HIV-1; infection; sarcoma, Kaposi; Zambia
Abbreviations: HHV-8, human herpesvirus 8; HIV-1, human immunodeficiency virus type 1; mIFA, monoclonal antibody-
enhanced immunofluorescence assay; Sf9, Spodoptera frugiperda clone 9.
Human herpesvirus 8 (HHV-8) is the infectious etiologic
agent of all forms of Kaposi’s sarcoma, primary effusion
lymphoma, and multicentric Castleman’s disease (1–4). The
global distributions of HHV-8 seroprevalence and Kaposi’s
sarcoma incidence are uneven (5). HHV-8 seroprevalence is
generally low in the United States and Northern Europe, but
it ranges from 20 percent to 80 percent in adult populations
in Africa and the Mediterranean (6–11). In a previous study,
He et al. (12) demonstrated that HHV-8 seroprevalence
among adolescent and childbearing women in Zambia is
approximately 50 percent.
The exact routes of HHV-8 transmission are still unclear
and may differ by geographic region and risk group. Hori-
zontal transmission via heterosexual and homosexual contact
has been reported in adults (13–15). Vertical transmission to
children seems to occur at a very low rate; a likely source
of nonsexual transmission is saliva, and the possibility
of transmission through breast milk is still controversial
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(16–18). A report from Uganda provided evidence for HHV-
8 transmission through blood transfusion (19). In Kaposi’s
sarcoma-endemic regions, primary HHV-8 infection has
been reported to occur during early childhood, suggesting
that transmission occurs early in life (20, 21). Among chil-
dren, HHV-8 seroprevalence generally increases with age,
which suggests that horizontal transmission may play an
important role (9, 21, 22). Epidemiologic studies from
sub-Saharan Africa report a seroprevalence of 20–68 per-
cent in adolescents (22–24). Socioeconomic factors such as
low parental education, low household income, and use of
a communal water source are associated with HHV-8 infec-
tion in African children; in addition, maternal coinfection
with HHV-8 and human immunodeficiency virus type 1
(HIV-1) may be an important risk factor (20, 22, 25–27).
In Zambia, coincident with the emergence of the HIV-1
epidemic, there was a significant increase in the incidence of
Kaposi’s sarcoma in adults and children (28–30). By 1992,
Kaposi’s sarcoma accounted for approximately 25 percent
of all childhood cancers diagnosed in Lusaka, the capital of
Zambia (31). Previously, Mantina et al. (18) reported infre-
quent detection of HHV-8 DNA in Zambian infants born to
HHV-8-infected mothers, suggesting a low level of in utero
transmission. However, this fails to account for the high
seroprevalence levels observed in early childhood. Zambian
children appear to contract HHV-8 infection early in life, but
the extent of HHV-8 infection, how children acquire the
virus, and whether HIV-1 infection in the child is a risk
factor remain unclear.
We evaluated early childhood incidence of HHV-8 sero-
conversion prospectively in a longitudinal cohort study of
infants followed from birth through age 48 months. Further-
more, we assessed whether maternal and pediatric HIV-1
infections were associated with higher risk of HHV-8 acqui-
sition during early childhood in Zambia.
MATERIALS AND METHODS
Setting
Between October 1998 and April 2004, pregnant women
visiting the labor ward at University Teaching Hospital in
Lusaka, Zambia, were screened for HHV-8 and HIV-1 (32).
Women in early stages of labor were enrolled in a prospective
cohort study after being counseled and educated about the study
and giving written informed consent. The study was approved
by the institutional review boards of the University of Zambia,
the University of Nebraska, and the University of Miami.
Study population
At delivery, mothers were divided into four groups based
on single or dual seropositivity for HIV-1 and/or HHV-8.
After delivery, mothers were encouraged to return with their
children for follow-up visits. A total of 1,424 mother-infant
pairs who returned for at least one postpartum visit consti-
tuted our longitudinal cohort (figure 1). This analysis in-
cluded 684 children who survived and were followed for
at least 24 months. Children who did not return at age 24
months (n ¼ 740) were excluded from this analysis; reasons
for exclusion included early mortality, early withdrawal, and
loss to follow-up before HIV-1 serostatus could be reliably
established. Children born to HIV-1-positive mothers were
tested at 24 months or later to determine HIV-1 status. Here
we report data collected from the 684 children who survived
beyond 24 months of age and were followed prospectively
for evaluation of both HHV-8 and HIV-1 seropositivity
between 12 and 48 months of age. Of these 684 children,
54 percent (370/684) of the infants were born to HHV-8-
seropositive mothers and 22 percent (151/684) were born to
HIV-1-seropositive mothers. By 24 months of age, 6 percent
(41/684) of the children tested positive for HIV-1.
Serologic testing for HHV-8 and HIV-1
HHV-8 serology. Blood specimens were collected annu-
ally from children at birth and 12, 24, 36, and 48 months after
birth. Specimens were coded by means of a unique identifi-
cation number assigned to each mother-infant pair and were
analyzed without knowledge of the personal identity of the
study participants. Plasma was screened for evidence of
HHV-8 seroconversion. Age at HHV-8 seroconversion was
defined as the age at which the first HHV-8-positive test result
was obtained using the assays described. To rule out detection
of transplacental maternal HHV-8 antibodies, plasma from
children younger than 12 months of age was not tested. In
addition, the plasma of all HHV-8-seropositive children at 12
months who were born to HHV-8-seropositive mothers was
titered at birth, at 6 months, and at 12 months to rule out
detection of maternal antibodies.
BC-3 monoclonal antibody-enhanced immunofluores-
cence assay. Antibodies against HHV-8 were detected by
monoclonal antibody-enhanced immunofluorescence assay
(mIFA) as described previously (33). BC-3 cells (American
Type Culture Collection, Manassas, Virginia) stimulated by
tetradecanoyl phorbol acetate were fixed and permeabilized,
and mIFA was carried out as described (32). To reduce
533 children born to
HIV-1-negative mother
Outcome
Child died: 7 
Mother died: 2 
Withdrawals: 19 
151 children born to
HIV-1-positive mother
Outcome
Child died: 14 
Mother died: 11 
Withdrawals: 1 
Cohort of 1,424 children born to mothers with known HIV-1 and
HHV-8 status at delivery  
684 children who
survived/returned at 24 months
740 children excluded from
this analyses 
FIGURE 1. Outline of a longitudinal study of human herpesvirus 8
(HHV-8) among children in Lusaka, Zambia, 1998–2004. Of the total
cohort, 740 children were excluded from the analysis because of early
mortality, early withdrawal, or loss to follow-up before human
immunodeficiency virus type 1 (HIV-1) serostatus could be reliably
established. ‘‘Outcome’’ indicates the reasons for attrition between 24
and 48 months of age.
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subjectivity in observing specific fluorescence, slides were
read independently by two laboratory workers. All plasma
determined to be positive by BC-3 mIFAwas confirmed using
Spodoptera frugiperda clone 9 (Sf9) mIFA as described be-
low. For determination of HHV-8 antibody titers, serial two-
fold dilutions of plasma were performed, and each dilution
was assayed using the BC-3 mIFA. The inverse of the last
dilution that tested positive was taken as the endpoint titer.
Sf9 monoclonal antibody-enhanced immunofluorescence
assay. Recombinant baculoviruses expressing the glutathi-
one S-transferase-tagged lytic proteins ORF65 and K8.1A
and the latent protein ORF73 (provided by Dr. Bala
Chandran, Rosalind Franklin University of Medicine and
Science, Chicago, Illinois), were used to develop an Sf9
mIFA. Baculovirus-infected Sf9 cells expressing glutathi-
one S-transferase alone were used as a negative control to
detect background and nonspecific fluorescence. All infec-
tions were initiated separately, harvested at 72 hours post-
infection, and fixed using the BC-3 cell method. The Sf9
mIFA procedure was similar to the BC-3 mIFA. A sample
was considered HHV-8-seropositive only if it was positive at
a standard serum dilution of 1:40 for both the BC-3 mIFA
and the Sf9 mIFA (with at least one antigen). The quality of
the slides was monitored for every batch, and appropriate
positive and negative controls were used every time mIFAs
were conducted.
HIV-1 serology. Plasma from mothers (at delivery) and
from children born to HIV-1-positive mothers (at 24 months
or older) was screened for HIV-1 antibodies. Human immu-
nodeficiency virus type 2 infection has not been reported in
Zambia (34, 35). Children born to HIV-1-negative mothers
were assumed to be HIV-1-negative. Children younger than
24 months were not screened for HIV-1 antibodies because
of the risk of detecting persisting transplacental maternal
antibodies. Plasma was screened by means of a standard
rapid HIV-1 kit (Capillus HIV-1/2 agglutination test kit;
Trinity Biotech PLC, Bray, Ireland) and confirmed by the
Abbott Determine HIV-1/2 enzyme immunoassay test kit
(Abbott Laboratories, Chicago, Illinois).
Statistical and analytic methods
The crude incidence rate per 100 child-years was calcu-
lated by dividing the number of new HHV-8 seroconverters
by the total number of child-years at risk and multiplying by
100. Children contributed HHV-8-free child-years at risk
until they tested positive for HHV-8. Because the actual date
of seroconversion within the 1-year interval is unknown,
a child was considered at risk for only half of the year in
which he/she tested positive. All data were right-censored at
48 months of age. We present the crude incidence rate per
100 child-years according to covariates. We also compared
stratum-specific incidence rates using the crude incidence
rate ratio and its 95 percent confidence interval. To evaluate
the risk of HHV-8 seroconversion over time, we estimated
hazard rate ratios and 95 percent confidence intervals using
Cox proportional hazards modeling in which we examined
various characteristics individually and simultaneously to
obtain adjusted hazard rate ratios and to generate hazard
curves that represented the child’s risk of seroconversion
for HHV-8 over time (36). All comparisons were considered
statistically significant at p  0.05. Data were analyzed
using the statistical software packages SAS, version 9.1
(SAS Institute, Inc., Cary, North Carolina), and SPSS, ver-
sion 15 (SPSS, Inc., Chicago, Illinois).
RESULTS
HHV-8 incidence and associated risk factors
Based on 1,532 total child-years of follow-up, the inci-
dence rate of HHV-8 seroconversion in Zambian children
was 13.8 infections per 100 child-years over 48 months
(table 1). We observed a statistically significant increased
risk of seroconversion among HIV-1-positive children after
adjusting for multiple covariates (adjusted hazard rate ratio¼
4.60, 95 percent confidence interval: 2.93, 7.22). No statisti-
cally significant difference in hazard rates was observed by
sex of the child or mother’s HHV-8 infection status at de-
livery. The association between HHV-8 seroconversion in
children and maternal HIV-1 seropositivity was no longer
statistically significant when results were adjusted for
HIV-1 seropositivity of the child. Similar results were ob-
served in children born to HIV-1-positive, HHV-8-negative
mothers in comparison with children born to HHV-8- and
HIV-1-negative mothers.
Table 2 shows a constant rate of annual HHV-8 infection
occurring in children, reported as the crude incidence rate per
100 child-years. We also examined these crude incidence rates
by maternal and child HIV-1 coinfection status and maternal
HHV-8 serostatus and observed results similar to those pre-
sented in table 1. Note that none of the HIV-1-infected chil-
dren in the cohort returned for follow-up after 36 months.
Figure 2 presents the probabilities of HHV-8 seroconver-
sion as hazard curves, stratified by covariates and adjusted
for confounders. These graphs show that there is little dif-
ference in the probability of HHV-8 seroconversion accord-
ing to maternal HHV-8 status (p ¼ 0.2), maternal HIV-1
infection (p ¼ 0.41), or maternal HIV-1 and HHV-8 co-
infection status (p ¼ 0.38) (panels A, B, and C). The most
important independent risk factor was HIV-1 infection in
children, where the probability of HHV-8 seroconversion
was significantly lower in the HIV-1-uninfected children
than in the infected children (p < 0.001) (panel D).
Figure 3 (panel A) shows the annual (12-month) percent-
age of children newly acquiring HHV-8 infection within each
period. Because HIV-1 infection of the child was the most
prominent risk factor observed for HHV-8 seroconversion,
we also present annual percentages of seroconversion accord-
ing to the child’s HIV-1 status at 24 months (panel B). This
figure shows that HHV-8 seroconversion in HIV-1-uninfected
children was essentially constant during each annual period,
while HHV-8 seroconversion in HIV-1-infected children was
significantly higher and increased during each annual period.
Variations in antibody titers in HHV-8-positive children
over time
The different HHV-8 seroreactivity patterns are summa-
rized in table 3. We monitored the HHV-8 antibody
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responses of 171 children who returned for all four follow-
up visits to study the temporal persistence of HHV-8
antibodies. Sixty percent (103/171) of these children were
persistently HHV-8-seronegative and 68 of the 171 children
(40 percent) seroconverted by 48 months, but only three of
the 68 children remained persistently HHV-8-seropositive at
all time points. We frequently observed fluctuations in an-
tibody titers, which dropped below the detection limit at one
or more time points, leading to seroreversion.
The titers of four representative patients are shown in
figure 4 to demonstrate the fluctuations in anti-HHV-8 anti-
body titers over time. Patients A and B were born to HHV-8-
seropositive mothers, and patients C and D were born to
HHV-8-seronegative mothers.
DISCUSSION
The major strengths of the present study were its size, its
prospective nature, and the availability of HHV-8 and HIV-1
coinfection data from mother-infant pairs collected at mul-
tiple time points from birth to 48 months of follow-up.
These strengths enabled us to provide the first documenta-
tion of annual HHV-8 incidence rates in early childhood in
an African endemic area. Our results indicate that the HIV-1
status of the child is a strong predictor of HHV-8 serocon-
version. Incidence rates were generally high among these
children between birth and 48 months of age. In addition,
fluctuations in detectable HHV-8 titers leading to serorever-
sions among HHV-8-seroconverted children may produce
frequent underestimation of childhood HHV-8 seropreva-
lence in cross-sectional studies.
The observed HHV-8 seroprevalence in Zambian children
is generally comparable to prevalences reported in cross-
sectional studies from other parts of sub-Saharan Africa
(17, 23, 26). While the prospective, longitudinal design of
this study makes it difficult to compare its results directly
with those of published cross-sectional studies conducted
in the region, HHV-8 seroprevalence of 20–60 percent
has been reported among young children (22–24). Kaplan-
Meier analysis (data not shown) estimating the probability
of HHV-8 seroconversion in this longitudinally followed
cohort revealed that more than 40 percent of the children sero-
converted for HHV-8 by age 48 months, with a clear increase
in HHV-8 seroprevalence with age. These results show that
children become infected at a young age in Zambia and that
adult seroprevalence levels may be reached relatively early
in life. These results indicate that HIV-1-infected children
are more likely to become HHV-8-infected, but it remains
unclear whether increased risk is due to HIV-1-infected
TABLE 1. Incidence of human herpesvirus 8 infection per 100 child-years and associated hazard rate ratios in a longitudinal cohort
study of 684 children, by maternal and child characteristics, Lusaka, Zambia, 1998–2004
Characteristic
No. of
children
%
No. of
HHV-8*-
positive
children
No. of
HHV-8-
free
child-years
Incidence
rate
per 100
child-years
Unadjusted
HRR*
95% CI*
Adjusted
HRR
95% CI
Total cohort 684 212 1,532.1 13.8
Sex of child
Male 349 51 101 799.3 12.6 0.84 0.64, 1.10 0.84y 0.64, 1.10
Female 335 49 111 732.8 15.2 1.00z 1.00z
Mother’s HIV-1* status at delivery
Uninfected 533 78 140 1,194.7 11.7 1.00z 1.00z
Infected 151 22 72 337.5 21.3 1.79 1.35, 2.38 1.16y 0.82, 1.63
Mother’s HHV-8 status at delivery
Negative 314 46 104 672.5 15.5 1.00z 1.00z
Positive 370 54 108 859.7 12.6 0.82 0.62, 1.07 0.84y 0.64, 1.10
Mother’s HIV-1 and HHV-8 status§
HIV-1 and HHV-8 240 35 63 511.8 12.3 1.00z 1.00z
HIV-1 and HHV-8þ 293 43 77 682.9 11.3 0.92 0.66, 1.29 0.91{ 0.65, 1.26
HIV-1þ and HHV-8 74 11 41 160.7 25.5 2.05 1.38, 3.03 1.29{ 0.83, 2.02
HIV-1þ and HHV-8þ 77 11 31 176.8 17.5 1.40 0.91, 2.15 0.94{ 0.59, 1.49
Child’s HIV-1 status at age
24 months
Uninfected 643 94 178 1,478.1 12.0 1.00z 1.00z
Infected 41 6 34 54.0 63.0 5.17 3.55, 7.52 4.60y 2.93, 7.22
* HHV-8, human herpesvirus 8; HRR, hazard rate ratio; CI, confidence interval; HIV-1, human immunodeficiency virus type 1.
y Adjusted for sex of the child, mother’s HHV-8 status, mother’s HIV-1 status, and child’s HIV-1 status at age 24 months.
zReference category.
§ A positive sign (þ) indicates seropositivity and a negative sign () indicates seronegativity.
{ Adjusted for sex of the child and child’s HIV-1 status at age 24 months.
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children’s having 1) a higher likelihood of being exposed to
HHV-8, 2) a higher likelihood of becoming infected when
exposed, or 3) a higher likelihood of antibody detection when
infected. In addition, the specific risk factors associated with
each of these possibilities have yet to be determined.
Potential routes of horizontal HHV-8 transmission are
poorly understood, but salivary contact may be the major
route of transmission in early childhood. Our laboratory and
others have previously found that HHV-8 DNA can be read-
ily detected in the saliva of infected persons and is detected
more frequently in persons with higher antibody titers (16,
37–39). While Zambian children are usually breast-fed up to
the age of 18–24 months, HHV-8 cannot be easily detected
in breast milk, suggesting that it is an unlikely source of
infection (16). We frequently observed HHV-8 seroconver-
sion in children born to mothers who were HHV-8-seroneg-
ative at delivery, indicating that horizontal transmission is
possible in early childhood. These results are consistent
with Mantina et al.’s finding that in utero infection of infants
is infrequent (18). However, we cannot rule out the possi-
bility that some children who are HHV-8-seropositive at 12
months have HHV-8 that is due to perinatal transmission.
Incidence in this cohort could still be underestimated if the
perinatally infected children seroreverted before age 12 months.
Determining serostatus in children below age 12 months is dif-
ficult because of the presence of maternal antibodies.
In this cohort, maternal HHV-8 infection was not an in-
dependent risk factor associated with transmission of HHV-
8 to children—a finding which was somewhat unexpected,
because in the early phase of life the mother is usually the
primary caregiver and has close contact with the child. This
suggests that mothers may not be the only source of trans-
mission to children and that other members of the household
or nonfamilial contacts could be responsible for horizontal
TABLE 2. Crude incidence of human herpesvirus 8 per 100 child-years and associated incidence rate ratios in a longitudinal cohort
study of 684 children, by maternal and pediatric human immunodeficiency virus type 1 status and maternal human herpesvirus 8
status, Lusaka, Zambia, 1998–2004
Characteristic and
study period
No. of
HHV-8*-
positive
children
No. of
HHV-8-
free
child-years
Crude
incidence
rate
per 100
child-years
No. of
HHV-8-
positive
children
No. of
HHV-8-
free
child-years
Crude
incidence
rate
per 100
child-years
IRR*
95%
confidence
interval
Total cohort All children
Birth to 12 months 92 638.4 14.4
Birth to 24 months 152 1,086.6 14.0
Birth to 36 months 195 1,393.2 14.0
Birth to 48 months 212 1,532.1 13.8
Sex of child Female Male IRRfemale/male
Birth to 12 months 51 309.5 16.5 41 329.0 12.5 1.32 0.88, 1.99
Birth to 24 months 78 521.2 15.0 74 565.4 13.1 1.14 0.83, 1.57
Birth to 36 months 101 668.3 15.1 94 724.9 13.0 1.17 0.88, 1.54
Birth to 48 months 111 732.8 15.2 101 799.3 12.6 1.20 0.92, 1.57
Mother’s HIV-1* status
at delivery
Negative Positive IRRpositive/negative
Birth to 12 months 62 501.5 12.4 30 136.9 21.9 1.77 1.15, 2.74
Birth to 24 months 98 844.7 11.6 54 241.9 22.3 1.92 1.38, 2.68
Birth to 36 months 131 1,081.3 12.1 64 311.9 20.5 1.69 1.26, 2.28
Birth to 48 months 140 1,194.7 11.7 72 337.5 21.3 1.82 1.37, 2.42
Mother’s HHV-8 serostatus
at delivery
Negative Positive IRRpositive/negative
Birth to 12 months 48 290.6 16.5 44 347.9 12.6 0.77 0.51, 1.15
Birth to 24 months 79 485.3 16.3 73 601.3 12.1 0.75 0.54, 1.02
Birth to 36 months 94 614.9 15.3 101 778.4 13.0 0.85 0.64, 1.12
Birth to 48 months 104 672.5 15.5 108 859.7 12.6 0.81 0.62, 1.06
Child’s HIV-1 status at age
24 months
Negative Positive IRRpositive/negative
Birth to 12 months 76 604.9 12.6 16 33.6 47.7 3.79 2.21, 6.50
Birth to 24 months 124 1,909.9 6.5 28 50.0 56.0 8.62 5.72, 13.00
Birth to 36 months 161 2,212.5 7.3 34 54.0 63.0 8.65 5.98, 12.53
Birth to 48 months 178 2,351.4 7.6 34 54.0 63.0 8.32 5.76, 12.00
* HHV-8, human herpesvirus 8; IRR, incidence rate ratio; HIV-1, human immunodeficiency virus type 1.
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transmission to young children. Some reports from sub-
Saharan Africa have shown a positive correlation between
the HHV-8 status of the mother and that of the child (24, 26).
However, other studies reported only a marginal-to-weak
correlation (25, 40), and a recent study demonstrated that
young infants’ risk of acquiring HHV-8 infection in South
Africa was not dependent on maternal serostatus (41).
Molecular evidence for this has come from Uganda, where
a mother and child were demonstrated to have different
HHV-8 subtypes (42). The strength of this association could
depend on locally common child-care practices, such as
kissing, premastication of food, or sharing of food and uten-
sils (43). The impact of such practices has not been explored
fully and may be different in Zambia than in other HHV-8-
endemic countries.
Brayfield et al. (16) previously reported risk factors asso-
ciated with HHV-8 infection in a much smaller group of
infants at 12 months while active follow-up of mother-infant
pairs was still ongoing. A commercially available enzyme-
linked immunosorbent assay was used to validate BC-3
mIFA results, and we observed that it underestimated
HHV-8 seroprevalence by missing patients with distinct
punctate nuclear staining, which led us to develop the Sf9
mIFA. We believe that patients with specific punctate stain-
ing could have low-titer antibodies that were missed by
enzyme-linked immunosorbent assay because of the higher
optical density cutoff values. Employing two assays as part
of an algorithm provided us with a reliable, highly specific
and conservative method. Sf9 mIFAs have matched negative
controls that are lacking for BC-3 mIFAs, thus contributing
to a low number of false-positive results. Analysis of a panel
of positive and negative control serum samples revealed
a high concordance between the two mIFAs (j ¼ 0.75; un-
published data). Zhu et al. (44) have suggested that confir-
mation of HHV-8 serostatus should not be based on a single
antigen, since infected persons may demonstrate variable
reactivity against different antigens. This variability may
explain the fluctuations in the anti-HHV-8 antibody titers
seen in this study and may explain why certain children have
undetectable antibody titers during follow-up. Such varia-
tion has been observed in adults, and seroreversion has been
reported for other herpesviruses and for hepatitis C virus
(45–49). HHV-8 DNA has been detected in certain HHV-8-
seronegative patients, and biopsy-proven Kaposi’s sarcoma
patients in full remission have been reported to undergo
HHV-8 seroreversion (50, 51).
FIGURE 2. Results from survival analysis estimating the probability of becoming seropositive for human herpesvirus 8 (HHV-8) in a longitudinal
cohort of 684 children followed from birth to 48 months of age, Lusaka, Zambia, 1998–2004. Results are presented by the HHV-8 serostatus of the
mother at delivery (panel A); the human immunodeficiency virus type 1 (HIV-1) infection status of the mother at delivery (panel B); maternal
coinfection with HIV-1 and HHV-8 at delivery (panel C); and the HIV-1 infection status of the child at age 24 months (panel D).
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Seroreversion may be partial or complete, resulting from
a loss of detectable titer to one or more antigens or a total
loss of all specific antibodies. We believe that the observed
seroreversions in our cohort could be both partial and com-
plete seroreversions. It is unlikely that the HHV-8 seropos-
itivity of children who tested positive at 12 months and
subsequently tested negative was due to residual maternal
HHV-8 antibodies, because all children born to HHV-8-
seropositive mothers were titered at birth and at age 6
months. Eight of 10 children who were seropositive at 12
months and were seronegative at all later time points were
born to HHV-8-seronegative mothers and were themselves
seronegative at birth. It is possible that the observed sero-
reversions in our cohort were due to antibody titers that were
below the limit of detection of our assays or due to the
stringent detection criteria used. However, seroreversion
has also been reported in studies using enzyme-linked im-
munosorbent assay (45). The lack of a gold-standard assay
with established 100 percent accuracy makes it difficult to
confirm these results. Performance studies of type-specific
commercial assays designed to distinguish between herpes
simplex virus types 1 and 2 have also reported that serore-
versions were introduced because of poor assay sensitivity
(52). An absence of antigenic stimulation after establish-
ment of latency or viral clearance could lead to serorever-
sion. In addition, immunocompetent children may be able to
efficiently control further reactivation, and thus the antibody
titers drop below detection levels. It has been proposed that
HHV-8-specific antibodies might be more readily detectable
due to broadening of epitope recognition over time or due to
subsequent reactivation after primary HHV-8 infection (45).
HIV-1-related immunosuppression has also been proposed to
be a factor responsible for HHV-8 seroreversion, especially in
the Zambian population, which is experiencing a generalized
HIV-1 epidemic. We observed that only four out of 41 HIV-1-
infected children underwent seroreversion at one or more time
points, but this number was too small for us to draw any
conclusion, and a much larger cohort of HIV-1-infected chil-
dren will be needed in order to understand this phenomenon.
Our study did have some important limitations. Although
the number of HIV-1-infected children followed was lim-
ited, we found significantly higher HHV-8 incidence among
HIV-1-infected children than among uninfected children.
The high rate of attrition in HIV-1-infected children proba-
bly led to an underestimate of the true HHV-8 incidence and
of the impact of child HIV-1 infection status on the risk of
HHV-8 acquisition during early childhood. The number of
children born to HIV-1-positive mothers was higher in the
group that was not included in the analysis. To be eligible
for inclusion in the analysis, a child had to survive and
return at 24 months of age for reliable detection of
HIV-1 antibodies. In addition, neither degree of clinical
FIGURE 3. Proportions (%) of 684 children seroconverting for
human herpesvirus 8 (HHV-8) during each annual follow-up period,
Lusaka, Zambia, 1998–2004. Results are presented for all children
followed to 48 months of age (panel A) and stratified by the human
immunodeficiency virus type 1 (HIV-1) infection status of the child at
age 24 months (panel B). None of the HIV-1-infected children
survived or returned beyond 36 months of age.
TABLE 3. Human herpesvirus 8 seroreactivity patterns among
171 children with completion of all planned study visits at 12,
24, 36, and 48 months of age, Lusaka, Zambia, 1998–2004
HHV-8* seroreactivity patterny
No. of
children
%12
months
24
months
36
months
48
months
    103 60.2
   þ 11 6.4
  þ þ 7 4.1
 þ þ þ 4 2.3
þ þ þ þ 3 1.8
þ þ þ  1 0.6
þ þ   2 1.2
þ    10 5.8
þ   þ 4 2.3
 þ   9 5.3
 þ þ  4 2.3
 þ  þ 7 4.1
  þ  6 3.5
Total for HHV-8-negative children 103 60.2
Total for HHV-8-positive children 68 39.8
Total for all children 171 100
* HHV-8, human herpesvirus 8.
y A positive sign (þ) indicates HHV-8 seropositivity at that age,
and a negative sign () indicates HHV-8 seronegativity.
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immunosuppression nor HIV-1 viral load could be assessed,
because methods for determining CD4 cell count and viral
load were not yet available in Zambia. Transmission from
siblings could not be examined because siblings were not
recruited. Attrition due to mortality was high in children,
especially those who were HIV-1-infected, because of lack
of availability of antiretroviral therapy at the time of the
study (53). None of the HIV-1-infected children returned
after 36 months, probably because of high mortality in this
group, which was without access to antiretroviral agents
during the time period of this study. Pediatric antiretroviral
therapy has since been implemented at primary health-care
clinics throughout Lusaka (54). Common reasons for with-
drawal from the study were religious beliefs, disapproval of
a spouse or family, or lack of interest. Some families were
untraceable because both the mother and the child died,
relocated, or provided a wrong address. Most members of
the study population were of lower socioeconomic status,
which contributed to their being highly mobile.
In conclusion, horizontal transmission appears to be the
major route of HHV-8 transmission in early childhood, and
HIV-1 infection of the child is an important risk factor for
HHV-8 acquisition in an area that is highly endemic for both
viruses. The frequent seroreversions observed demonstrate
that cross-sectional serologic screening for HHV-8 under-
estimates true rates of HHV-8 infection and may not provide
a true representation of HHV-8 prevalence and incidence in
a population.
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